Yüklüyor......
Lenalidomide in Diffuse Large B-Cell Lymphomas
Diffuse Large B-cell Lymphomas (DLBCL) are the most frequent Non-Hodgkin Lymphomas (NHL). The addition of Rituximab to the standard chemotherapy CHOP improved the outcome in this patients, but so far 40% of patients experienced relapse or progressive disease. Lenalidomide, an immunomodulatory agent,...
Kaydedildi:
| Asıl Yazarlar: | , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Hindawi Publishing Corporation
2012
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3390034/ https://ncbi.nlm.nih.gov/pubmed/22792112 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2012/498342 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|